Evidence map›Paper›PMID 25723057›Full record

ReviewCell cycle (Georgetown, Tex.)2015

Roles of TRAF3 in T cells: many surprises.

Zuoan Yi, Alicia M Wallis, Gail A Bishop

Open access · bronzeAbstract readReview
In one paragraph

Review in Cell cycle (Georgetown, Tex.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  5. TRAF3: Guardian of T lymphocyte functions.Frontiers in immunology · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Zuoan Yia Departments of Microbiology ; University of Iowa ; Iowa City , IA USA.
Alicia M Wallis
Gail A Bishop
University of Iowa · USIowa City VA Medical Center · US

Funding

INTERDISCIPLINARY IMMUNOLOGY TRAINING PROGRAMT32AI007260 · NIAID · UNIVERSITY OF IOWA · PI BUTLER, NOAH SULLIVAN, WU, LI · 1986 to 2023
$5.7M
The Roles of TRAF3 in Lymphocyte SignalingR01AI028847 · NIAID · UNIVERSITY OF IOWA · PI BISHOP, GAIL A. · 1996 to 2011
$3.1M
NIAID NIH HHS R01AI28847NIAID NIH HHS T32AI007260
6 · The paper itself

Abstract

Tumor necrosis factor receptor (TNFR)-associated factor 3 (TRAF3) is broadly involved in different receptor-mediated signaling pathways. Considerable progress was made recently in understanding the role of TRAF3 in T cell biology. Here we review these new findings about how TRAF3 participates in T cell development and function. The different roles of TRAF3 in distinct immune cells are also compared. That TRAF3 is required for T cell effector functions, and invariant Natural Killer T cell function and development, was unexpected. Another surprising finding is that TRAF3 normally restrains regulatory T cell development. It is now clear that TRAF3 regulates signaling to T cells not only through costimulatory members of the TNFR superfamily, but also through the T cell receptor complex, and cytokine receptors. The diverse roles it plays support the multifaceted nature of this molecule. How TRAF3 mediates integration of different signaling cascades is an important topic for future study.

Indexed as

AnimalsHumansKiller Cells, NaturalNF-kappa BReceptors, Interleukin-2Signal TransductionT-LymphocytesT-Lymphocytes, RegulatoryTNF Receptor-Associated Factor 3NF-kappa BReceptors, Interleukin-2TNF Receptor-Associated Factor 3adaptor moleculeDC, dendritic cellIBD, inflammatory bowel diseaseICOS, inducible co-stimulatorIKK, IκB kinaseIL-2, interleukin-2IL-2 receptoriNKT cell, invariant Natural Killer T cellinvariant Natural Killer T cellJak1, Janus kinase 1LMC, litter mate controlLMP1, latent membrane protein-1MAPK, mitogen-activated protein kinaseMΦ, macrophageNIK, NF-κB inducing kinaseNLR, nucleotide binding-oligomerization domain (NOD)-like receptorregulatory T cellRLR, retinoic acid-inducible gene (RIG)-I-like receptorsignaling pathwaySLAM, signaling lymphocyte activation moleculeSOCS1, Suppressor of cytokine signaling 1T cellT cell receptorTcm cell, central memory T cellTCPTP, T cell protein tyrosine phosphataseTCR, T cell receptorTem cell, effector memory T cellTFH, follicular helper T cellTFR, follicular Treg cellTLR, Toll-like receptorTNFR, Tumor necrosis factor receptorTRAF3TRAF3, TNFR-associated factor 3Treg cell, regulatory T cellT-TRAF3−/−, CD4CreTRAF3flox/flox

Identifiers

PMID25723057
PMCPMC4613145
OpenAlexW1622385782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.